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Summary
Background Colorectal cancer is the third most common cancer worldwide and has a high mortality rate. We tested 
the hypothesis that only one ﬂ exible sigmoidoscopy screening between 55 and 64 years of age can substantially reduce 
colorectal cancer incidence and mortality.
Methods This randomised controlled trial was undertaken in 14 UK centres. 170 432 eligible men and women, who 
had indicated on a previous questionnaire that they would accept an invitation for screening, were randomly allocated 
to the intervention group (oﬀ ered ﬂ exible sigmoidoscopy screening) or the control group (not contacted). 
Randomisation by sequential number generation was done centrally in blocks of 12, with stratiﬁ cation by trial centre, 
general practice, and household type. The primary outcomes were the incidence of colorectal cancer, including 
prevalent cases detected at screening, and mortality from colorectal cancer. Analyses were intention to treat and per 
protocol. The trial is registered, number ISRCTN28352761.
Findings 113 195 people were assigned to the control group and 57 237 to the intervention group, of whom 112 939 and 
57 099, respectively, were included in the ﬁ nal analyses. 40 674 (71%) people underwent ﬂ exible sigmoidoscopy. 
During screening and median follow-up of 11·2 years (IQR 10·7–11·9), 2524 participants were diagnosed with 
colorectal cancer (1818 in control group vs 706 in intervention group) and 20 543 died (13 768 vs 6775; 727 certiﬁ ed 
from colorectal cancer [538 vs 189]). In intention-to-treat analyses, colorectal cancer incidence in the intervention 
group was reduced by 23% (hazard ratio 0·77, 95% CI 0·70–0·84) and mortality by 31% (0·69, 0·59–0·82). In per-
protocol analyses, adjusting for self-selection bias in the intervention group, incidence of colorectal cancer in people 
attending screening was reduced by 33% (0·67, 0·60–0·76) and mortality by 43% (0·57, 0·45–0·72). Incidence of 
distal colorectal cancer (rectum and sigmoid colon) was reduced by 50% (0·50, 0·42–0·59; secondary outcome). The 
numbers needed to be screened to prevent one colorectal cancer diagnosis or death, by the end of the study period, 
were 191 (95% CI 145–277) and 489 (343–852), respectively.
Interpretation Flexible sigmoidoscopy is a safe and practical test and, when oﬀ ered only once between ages 55 and 
64 years, confers a substantial and longlasting beneﬁ t.
Funding Medical Research Council, National Health Service R&D, Cancer Research UK, KeyMed.
Introduction
Colorectal cancer is the third most frequently diagnosed 
cancer worldwide, accounting for more than 1 million 
cases and 600 000 deaths every year.1 Survival is strongly 
related to stage at diagnosis, with survival rates of 90% 
for localised cases.2 Three randomised controlled trials3 
have shown that biennial screening with the faecal occult 
blood test, which detects early cases, reduces mortality by 
around 25% in users of the test, and many countries have 
introduced screening programmes based on this test.4
Screening can potentially prevent colorectal cancers, 
because most arise from adenomas: predominantly 
symptomless growths that develop in 20–30% of the 
population.5,6 Two-thirds of colorectal cancers and 
adenomas are located in the rectum and sigmoid colon, 
which can be examined by ﬂ exible sigmoidoscopy. We 
have shown that ﬂ exible sigmoidoscopy is well 
accepted, safe, and quick,7–9 and would therefore be a 
suitable method for popu la tion screening if evidence 
of a worthwhile beneﬁ t is shown. 
We did a large randomised trial to examine the 
hypothesis that only one ﬂ exible sigmoidoscopy screen 
undertaken between ages 55 and 64 years is a cost-
eﬀ ective and acceptable method to reduce colorectal 
cancer incidence and mortality. Our hypothesis is based 
on observations suggesting that most people who develop 
a distal colon cancer will have developed an adenoma by 
60 years of age,10 and that removal of adenomas by 
sigmoidoscopy provides long-term protection against the 
development of distal colorectal cancer.11 Results from 
several epidemiological studies lend support to this 
hypothesis.12–14 Baseline ﬁ ndings from the trial were 
published in 2002,7 and in this Article we report the 
results after a median of 11 years of follow-up.
Methods
Study design and participants
The design and rationale for the trial protocol have been 
described previously.15 We initially undertook two pilot 
studies to reﬁ ne the protocol and to conﬁ rm the 
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assumptions on which our sample-size calculations were 
based.16 Recruitment and screening started in November, 
1994, and were completed in March, 1999. The study took 
place in 14 UK centres: 11 in England, two in Wales, and 
one in Scotland. Ethics approval was obtained from local 
research ethics committees, and all participants undergoing 
screening provided written informed consent. 
All men and women aged between 55 and 64 years and 
registered with participating general practices were 
eligible to take part unless they met the following 
exclusion criteria: inability to provide informed consent; 
history of colorectal cancer, adenomas, or inﬂ ammatory 
bowel disease; severe or terminal disease; life expectancy 
less than 5 years; or sigmoidoscopy or colonoscopy within 
the previous 3 years. Eligible individuals were sent brief 
information about colorectal cancer and the screening 
test, together with a short questionnaire including the 
question: “If you were invited to have the bowel-cancer 
screening test, would you take up the oﬀ er?” Individuals 
reporting a strong family history of colorectal cancer (two 
or more close relatives), or symptoms of colorectal cancer 
were managed outside the trial because randomisation 
would not have been in their interest.
Randomisation and masking
Eligible individuals, who indicated in the questionnaire 
that they would take up the oﬀ er of screening if invited, 
were randomly allocated to the intervention (ﬂ exible 
sigmoidoscopy screening) or control groups in the 
ratio 1:2. Randomisation was stratiﬁ ed by trial centre, 
general practice within centre, and household type 
(deﬁ ned by the number of eligible people in the 
household who indicated that they would take up the 
oﬀ er of screening: single man, single woman, couples, 
other). Sequentially numbered randomisation was 
done centrally in blocks of 12, but with the added 
constraint of no more than three consecutive allocations 
to one group within or across blocks. The constraint on 
blocks contributed to slightly more than a third of 
individuals being randomly allocated to the intervention 
group. Participants randomly assigned to screening 
were oﬀ ered an appointment; those in the control 
group were not contacted. 
Screening procedure
Flexible sigmoidoscopy screening was done in hospital 
endoscopy clinics. Details of the screening procedure 
are described elsewhere.7 Brieﬂ y, participants underwent 
ﬂ exible sigmoidoscopy with polypectomy for small 
polyps and referral for colonoscopy if they had polyps 
meeting any of the following high-risk criteria: 1 cm or 
larger; three or more adenomas; tubulovillous or villous 
histology; severe dysplasia or malignant disease; or 20 or 
more hyperplastic polyps above the distal rectum. 
Individuals who had no polyps or only low-risk polyps at 
ﬂ exible sigmoidoscopy were discharged. The occurrence 
of adverse physical and psychological eﬀ ects associated 
with the whole screening procedure, and the quality of 
the examinations, were carefully monitored and have 
been reported elsewhere.7,9,17,18
Follow-up and endpoints
Since 1999, trial participants have been ﬂ agged on the 
National Health Service Central Register (NHSCR), 
which provides information about name changes, 
emigrations, cancer registrations, and dates of death. 
Information about causes of death as noted in the death 
certiﬁ cate was provided by the Oﬃ  ce for National 
Statistics (ONS). UK cancer registries routinely update 
the NHSCR with cancer registrations, but there can be a 
time lag. To improve the speed of ascertainment of new 
cancer diagnoses, we obtained approvals to collect 
information directly from cancer registries, Hospital 
Episodes Statistics, and the NHS Bowel Cancer Screening 
Programme databases. All colorectal cancer diagnoses 
were conﬁ rmed by the registries.
Colorectal cancer sites were deﬁ ned by the International 
Classiﬁ cation of Diseases, tenth revision (ICD-10), and 
included codes C18–C20. Lesions overlapping 
375 744 men and women aged 55–64 years
in 506 general practices assessed
for eligibility
7602 excluded by general practitioner
368 142 sent questionnaire to establish
interest in screening
194 726 responded yes interested
170 432 randomised
113 195 allocated to
control group
112 939 analysed 57 099 analysed
40 621 screened
16 478 not screened
57 237 allocated to
intervention group
138 excluded from analysis
55 had died*
76 had previous colorectal cancer*
6 duplicate study numbers
1 outside age range
256 excluded from analysis
107 had died*
142 had previous colorectal cancer*
2 emigrated*
5 duplicate study numbers
173 416 excluded
91 421 no response
65 473 responded no
2642 responded unsure
13 880 returned undelivered
24 294 not randomised
8280 ineligible
16 014 excess not required
Figure 1: Trial proﬁ le
*Prerandomisation events.
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neighbouring sites (C18.8) were allocated a code for the 
more distal site, and synchronous lesions were recorded 
as separate instances of cancer. Distal cancer was deﬁ ned 
as C18.7, C19, and C20 (sigmoid colon and rectum), 
proximal cancer as C18.0–C18.6 (all sites in the colon 
proximal to the sigmoid), and site unspeciﬁ ed cancer as 
C18 and C18.9.
Morphology of colorectal neoplasia was coded with 
ICD-O2 codes. We included all codes relating to invasive 
adenocarcinomas (81403, 82103, 82203, 82603, 82613, 
82633, 84803, 84813, 84903), and carcinoma not otherwise 
speciﬁ ed (80103) for cancers in eligible sites that were 
diagnosed on clinical grounds only.
All deaths certiﬁ ed by the ONS as having colorectal 
cancer as an underlying cause were included as an 
endpoint in the analysis of cause-speciﬁ c mortality. A 
second analysis was done after blinded veriﬁ cation of 
assignment of colorectal cancer as an underlying cause 
of death according to the rules described in the 
webappendix. Death certiﬁ cates were supplemented by 
clinical information when available and scrutinised 
by an expert and independent coder, who was masked to 
the trial allocation.
Statistical analysis
The sample size was calculated to give 90% power to 
detect a 20% diﬀ erence between the intervention and 
control groups in incidence of colorectal cancer at 10 years 
and mortality at 15 years since randomisation, assuming 
a conservative attendance rate for screening of 55%.15 
Because of the higher than expected attendance rates, 
revised estimates suggested that the required number of 
endpoints to show a signiﬁ cant diﬀ erence in mortality 
would be achieved at 11 years.19
The primary outcomes in this analysis were colorectal 
cancer incidence and mortality. Secondary outcomes were 
incidence of distal and proximal cancer, all-cause mortality, 
and mortality due to non-colorectal cancer causes.
The cutoﬀ  for follow-up for this analysis was Dec 31, 
2008, although cancer registration was not expected to be 
complete for the ﬁ nal year. All time-to-event data were 
censored at emigration, end of follow-up, or death. Only 
one colorectal cancer per patient was counted in the 
estimation of incidence of each cancer outcome. In 
estimation of the incidence of colorectal cancer of all 
sites, the earliest diagnosis in each patient was used. For 
the estimation of site-speciﬁ c (distal or proximal) cancer 
rates, we used the earliest cancer in that site category.
Results are presented as average incidence rates per 
100 000 person-years. Intention-to-treat and per-protocol 
analyses were undertaken. One minus the Kaplan-Meier 
estimator of the survival function was used to illustrate 
time to colorectal cancer and death. The proportionality 
assumption was violated for incidence of distal and all 
colorectal cancers. However, the hazards were pro-
portional for most of follow-up, from about 3 years 
onwards; therefore we used univariate Cox proportional 
hazards models to estimate hazard ratios and 95% CIs 
for the intention-to-treat analyses. The Schoenfeld test 
did not identify any violations of the assumption of 
proportionality for outcomes other than incidence of 
distal and all colorectal cancers. Hazard ratios by sex and 
age group (55–59 and 60–64 years) were illustrated by 
Forest plots, and signiﬁ cant diﬀ erences were tested for 
by the addition of appropriate interaction terms to the 
models. In the per-protocol analyses, Cuzick and 
colleagues’20 method was used to estimate hazard ratios 
and CIs adjusted for non-compliance. The numbers 
needed to screen to prevent one colorectal cancer or one 
death due to colorectal cancer, with 95% CIs, were 
calculated with Tabar and colleagues’ method.21
The trial is registered, number ISRCTN28352761.
Control group (n=112 939) Intervention group (n=57 099) Hazard ratio (95% CI); 
intervention vs control group
p value
Cases Person-years Rate (per 100 000 
person-years; 95% CI)
Cases Person-years Rate (per 100 000 
person-years; 95% CI)
Incidence
All sites 1818* 1 218 334 149 (143–156) 706*† 616 981 114 (106–123) 0·77 (0·70–0·84) <0·0001
Distal: rectum and sigmoid colon 1192‡ 1 220 175 98 (92–103) 386†‡ 618 053 62 (57–69) 0·64 (0·57–0·72) <0·0001
Proximal 628‡ 1 222 639 51 (48–56) 311†‡ 618 962 50 (45–56) 0·98 (0·85–1·12) 0·75
Mortality
All-cause 13 768 1 224 523 1124 (1106–1143) 6775 620 045 1093 (1067–1119) 0·97 (0·94–1·00) 0·0519
Colorectal cancer§ 538 1 224 523 44 (40–48) 189 620 045 30 (26–35) 0·69 (0·59–0·82) <0·0001
Non-colorectal cancer causes§ 13 230 1 224 523 1080 (1062–1099) 6586 620 045 1062 (1037–1088) 0·98 (0·95–1·01) 0·25
Colorectal cancer (veriﬁ ed¶) 637 1 224 523 52 (48–56) 221 620 045 36 (31–41) 0·68 (0·59–0·80) <0·0001
Non-colorectal cancer causes (veriﬁ ed¶) 13 131 1 224 523 1072 (1054–1091) 6554 620 045 1057 (1032–1083) 0·99 (0·96–1·02) 0·33
*41 cancers with site not speciﬁ ed were included, 29 in control group and 12 in the intervention group. Only the earliest cancer was counted for patients with more than one cancer. †140 patients had cancers 
detected at baseline screening (126 distal cancers and 14 proximal cancers). ‡34 patients had both a distal and a proximal cancer (19 synchronous and 15 metachronous): 31 patients in control group and three 
in the intervention group. §Deaths certiﬁ ed by the Oﬃ  ce for National Statistics as colorectal cancer as underlying cause of death by automatic coding. ¶Assignment of colorectal cancer as underlying cause of 
death by independent expert coder. 
Table 1: Colorectal cancer incidence and mortality in control and intervention groups
See Online for webappendix
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Time from randomisation (years)
Control and intervention groups
Control
Intervention
A
Number at risk
Control 112 939 11 1113 108 951 106 363 103 470 99 629 18 553
Intervention   57 099  56 111   55 106   53 893   52 501 50 597   9459
0 8642 101 9753 11 12
Time from randomisation (years)
Control, screened, and not screened groups
Control
Screened
Not screened
B
 Number at risk
 Control 112 939 11 1 113 108 951 106 363 103 470 99 629 18 553
 Screened 40 621 40 129 39 547 38 820 37 962 36 720  7131
 Not screened 16 478 15 982 15 559 15 073 14 539 13 877 2328
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Number at risk
Control 112 939 11 1 165 109 053 106 529 103 693 99 926 18 619
Intervention 57 099   56 153   55 172   53 985   52 614  50 744   9492
0 8642 101 9753 11 12
D
 Number at risk
 Control 112 939 11 1 165 109 053 106 529 103 693 99 926 18 619
 Screened   40 621   40 156   39 595   38 885    38 043  36 827    7157
 Not screened   16 478   15 997   15 577   15 100    14 571  13 917   2335
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E
Number at risk
Control 112 939 111 268 109 218 106 738 103 969 100 290 18 679
Intervention   57 099   56 258    55 258   54 071   52 694   50 823   9505
0 8642 101 9753 11 12
F
 Number at risk
 Control 112 939 111 268 109 218 106 738 103 969 100 290 18 679
 Screened  40 621   40 252   39 657   38 939    38 087   36 851    7160
 Not screened 16 478  16 006  15 601   15 132   14 607   13 972   2345
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G
Number at risk
Control 112 939 11 1 321 109 319 106 907 104 196 100 597 18 748
Intervention   57 099   56 300   55 325  54 164   52 809   50 972    9539
0 8642 101 9753 11 12
H
 Number at risk
 Control 112 939 11 1 321 109 319 106 907 104 196 100 597 18 748
 Screened  40 621  40 279   39 705  39 004    38 169   36 959    7187
 Not screened  16 478  16 021   15 620  15 160   14 640   14 013  2352
Figure 2: Kaplan-Meier 
estimates of cumulative 
incidence and mortality
Colorectal cancer incidence 
(A and B), distal cancer 
incidence (C and D), proximal 
cancer incidence (E and F), and 
colorectal cancer mortality 
(G and H). A, C, E, and G are 
intention-to-treat analyses. 
B, D, F, and H are per-protocol 
analyses.
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Role of the funding source
The sponsors of the study had no role in study design, data 
collection, data analysis, data interpretation, or the writing 
of the report. KW, IKH, RE, and SD had full access to the 
data, and WA had ﬁ nal responsibility for submission.
Results
Figure 1 shows the trial proﬁ le. 506 (88%) general 
practices, with 2102 general practitioners, agreed to 
participate in this study. Local health authorities identiﬁ ed 
375 744 patients of the practices, who were aged between 
55 and 64 years at the time of the request for data, and 
general practitioners identiﬁ ed 7602 of them as being 
ineligible. Questionnaires to assess interest in screening 
were sent by mail to 368 142 people (50% women), of 
whom 194 726 (53%) responded that they would take up 
the oﬀ er of screening if invited. Of these, 24 294 people 
were excluded (ﬁ gure 1), and 170 432 were randomly 
assigned: 113 195 to the control group and 57 237 to the 
intervention group. 
40 674 (71%) people attended their screening 
appointment. After screening, 38 525 (95%) were 
discharged because either no polyps or only low-risk 
polyps were detected. 2131 (5%) people were referred 
for colonoscopy because high-risk polyps were detected, 
of whom 2051 underwent the procedure and 1745 
entered a surveillance programme.
When the cohort was matched with NHSCR data, 
162 people (107 control group and 55 intervention group) 
were found to have died on or before the date of 
randomisation, 218 people (142 control group and 
76 intervention group) had colorectal cancer diagnosed 
before randomisation, and two (both controls) had 
emigrated. One individual, who was assigned to the 
intervention group and attended, had an incorrect birth 
date (aged 42 years at randomisation). These people were 
excluded. 11 individuals were randomised twice (mainly 
because they changed general practitioner; ﬁ ve control 
group and six intervention group) and the second 
randomisation was invalidated.
The ﬁ nal analysis cohort consisted of 170 038 parti-
cipants: 112 939 people were assigned to the control 
group and 57 099 to the intervention group (of whom 
40 621 [71%] attended for screening). There were 29 105 
(51%) women in the intervention group and 57 602 
(51%) in the control group, and the mean age was 
60 years (SD 2·9) in both groups. 
Control group (n=112 939) Intervention group (n=57 099) Hazard ratio 
(95% CI); screened 
vs control group*
Not screened (n=16 478) Screened (n=40 621)
Cases Person-
years
Rate (per 100 000 
person-years; 95% CI)
Cases Person-
years
Rate (per 100 000 
person-years; 95% CI)
Cases Person-
years
Rate (per 100 000 
person-years; 95% CI)
Incidence
All sites 1818† 1 218 334 149 (143–156) 261† 172 260 152 (134–171) 445†‡ 444 721 100 (91–110) 0·67 (0·60–0·76)
Distal: rectum and sigmoid colon 1192§ 1 220 175 98 (92–103) 171§ 172 565 99 (85–115) 215‡§ 445 488 48 (42–55) 0·50 (0·42–0·59)
Proximal 628§ 1 222 639 51 (48–56) 87§ 172 879 50 (41–62) 224‡§ 446 084 50 (44–57) 0·97 (0·80–1·17)
Mortality
All-cause 13 768 1 224 523 1124 (1106–1143) 2713 173 191 1566 (1509–1627) 4062 446 854 909 (881–937) 0·95 (0·91–1·00)
Colorectal cancer¶ 538 1 224 523 44 (40–48) 78 173 191 45 (36–56) 111 446 854 25 (21–30) 0·57 (0·45–0·72)
Non-colorectal cancer causes¶ 13 230 1 224 523 1080 (1062–1099) 2635 173 191 1521 (1461–1581) 3951 446 854 884 (857–912) 0·97 (0·93–1·02)
Colorectal cancer (veriﬁ ed||) 637 1 224 523 52 (48–56) 94 173 191 54 (44–66) 127 446 854 28 (24–34) 0·56 (0·45–0·69)
Non-colorectal cancer causes 
(veriﬁ ed||)
13 131 1 224 523 1072 (1054–1091) 2619 173 191 1512 (1455–1571) 3935 446 854 881 (854–909) 0·98 (0·93–1·03)
*Adjusted for non-compliance with screening. †41 cancers with site not speciﬁ ed were included, 29 in control group and 12 in the intervention group (four not screened and eight screened). Only the earliest 
cancer was counted for patients with more than one cancer. ‡140 patients had cancers detected at baseline screening (126 distal cancers and 14 proximal cancers). §34 patients had both a distal and a proximal 
cancer (19 synchronous and 15 metachronous): 31 patients in the control and three in the intervention group (one not screened and two screened). ¶Deaths certiﬁ ed by the Oﬃ  ce for National Statistics as 
colorectal cancer as underlying cause of death by automatic coding. ||Assignment of colorectal cancer as underlying cause of death by independent expert coder. 
Table 2: Colorectal cancer incidence and mortality by randomisation and compliance with screening
Time from randomisation (years)
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Figure 3: Smoothed yearly hazard rates for distal cancer (rectum and sigmoid 
colon)
Curves are truncated at 10 years of follow-up because of incomplete 
ascertainment of cancers in the ﬁ nal calendar year of the study.
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The NHSCR was unable to trace six people in the 
control group and six in the intervention group, two of 
whom were screened. A further 234 (<1%) in the 
intervention group and 451 (<1%) in the control group 
emigrated. The median follow-up time to death, 
emigration, loss to follow-up, or Dec 31, 2008, was 
11·2 years (IQR 10·7–11·9).
In the analysed cohort, 2674 colorectal cancers were 
reported of which 2588 (97%) were histologically 
conﬁ rmed, 68 (3%) were diagnosed clinically, and 18 (1%) 
were ascertained via the death certiﬁ cate only. We 
excluded 26 carcinoid tumours, 19 in-situ lesions, ﬁ ve 
squamous cell carcinomas, two small cell carcinomas, 
two gastrointestinal stromal tumours, one baso-
squamous carcinoma, one leiomyosarcoma, and one 
nodal marginal zone lymphoma.
2617 colorectal cancers were included in the analyses. 
These were diagnosed in 2524 participants: 1818 in the 
control group and 706 in the intervention group. 
2438 participants had one colorectal cancer diagnosed 
and 86 people had two or more (34 had both distal and 
proximal cancers). Distal cancers were diagnosed in 
1192 people in the control group and in 386 in the 
intervention group (126 detected at screening). Proximal 
cancers were diagnosed in 628 people in the control 
group and in 311 people in the intervention group 
(14 detected at screening).
In an intention-to-treat analysis, the incidence of 
colorectal cancers (all sites) was signiﬁ cantly lower in the 
intervention than in the control group (table 1, ﬁ gure 2A). 
The incidence of distal colon cancer was reduced by 36%, 
and proximal incidence by 2% (table 1; ﬁ gure 2C and 2E). 
When the groups were examined according to 
attendance for screening (per-protocol analysis), the 
incidence of colorectal cancer in non-attenders was very 
similar to that in the control group (table 2, ﬁ gure 2B). 
The incidence, adjusted for non-compliance, in those 
who were screened compared with controls was reduced 
by 33% for all colorectal cancer sites, by 50% for the distal 
colon, and by 3% for the proximal colon (table 2; 
ﬁ gure 2B, 2D, and 2F).
Cumulative incidence for all colorectal and distal 
cancers, in per-protocol analysis, was higher in the 
intervention group than the control group for about the 
ﬁ rst 4 years because of early detection of prevalent 
cancers at screening (ﬁ gure 2B and 2D). After this point, 
the curves began to diverge and the cumulative incidence 
rates became higher in the control group. The smoothed 
yearly hazard rates for distal cancers (ﬁ gure 3) showed a 
peak in year 1 because of the inclusion of prevalent 
cancers in the screened group, and after this point 
incidence was low compared with the control group. We 
recorded no apparent diﬀ erences between the 
intervention and control groups in the curves for 
cumulative inci dence of proximal cancer at any follow-up 
time (ﬁ gure 2E and 2F).
We estimated the number of people who needed to be 
screened to prevent one colorectal cancer diagnosis over 
the study period to be 191 (95% CI 145–277; table 3).
There were 20 543 deaths in the trial cohort (13 768 in 
control group, 6775 in the intervention group) of which 
727 had colorectal cancer as an underlying cause 
(538 control group, 189 intervention group) according to 
death certiﬁ cation by the ONS. Cumulative all-cause 
mortality at the end of the follow-up period was 
11·24 (95% CI 11·06–11·43) deaths per 1000 person-years 
in the control group and 10·93 (10·67–11·19) per 
1000 person-years in the intervention group (table 1). 
Mortality from colorectal cancer as certiﬁ ed by the ONS 
was reduced by 31% in the intervention group in the 
intention-to-treat analysis (table 1, ﬁ gure 2G). In an 
adjusted per-protocol analysis, we recorded a 43% 
reduction in death due to colorectal cancer in people 
Control group (n=112 939) Intervention group Number of events 
expected in 
intervention group
Number of events 
prevented in 
intervention group
Number needed to 
screen to prevent 
one event (95% CI)
Total (n=57 099) Screened (n=40 621)
n Rate (per 1000; 
95% CI)
n Rate (per 1000; 
95% CI)
n Rate (per 1000; 
95% CI)
Colorectal cancer diagnosis 1818 16·1 (15·4–16·9) 706 12·4 (11·5–13·3) 445 11·0 (10·0–12·0) 919 213 191 (145–277)
Colorectal cancer death* 538 4·8 (4·4–5·2) 189 3·3 (2·9–3·8) 111 2·7 (2·3–3·3) 272 83 489 (343–852)
Colorectal cancer death (veriﬁ ed†) 637 5·6 (5·2–6·1) 221 3·9 (3·4–4·4) 127 3·1 (2·6–3·7) 322 101 402 (291–647)
*Deaths certiﬁ ed by the Oﬃ  ce for National Statistics as colorectal cancer as underlying cause of death by automatic coding. †Assignment of colorectal cancer as underlying cause of death by independent expert coder. 
Table 3: Cumulative incidence of and mortality from colorectal cancer, and the number needed to screen to prevent one event in the present follow-up period
Cases/person-years
Screened group Control group
Age group (years)
55–59 181/226 033 766/621 428
60–64 264/218 687 1052/596 907
Sex
Women 175/223 534 697/631 639
Men 270/221 187 1121/586 695
Overall 445/444 721 1818/1 218 334
0·4 0·6 0·80·675
Hazard ratio (95% CI)
1
Figure 4: Hazard ratios for colorectal cancer (all sites) in screened versus control groups by age group and sex
Hazard ratios are adjusted for non-compliance with screening.
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who attended screening compared with controls 
(table 2, ﬁ gure 2H). Screening had no signiﬁ cant eﬀ ect 
on mortality due to non-colorectal cancer causes in either 
the intention-to-treat or per-protocol analyses (table 1, 
table 2). 
We estimated the number of people who needed to be 
screened to prevent one death due to colorectal cancer to 
be 489 (95% CI 343–852; table 3). 
Independent veriﬁ cation of death certiﬁ cates identiﬁ ed 
a further 132 deaths that were probably attributable to 
colorectal cancer and one that probably should not have 
been attributed to colorectal cancer. Adjustment for these 
deaths in our analyses had almost no eﬀ ect on hazard 
ratios for rates of colorectal cancer mortality or non-
colorectal cancer mortality (table 1, table 2), but 
substantially reduced the number needed to screen to 
prevent one death (table 3).
We recorded no signiﬁ cant diﬀ erences between men 
and women or between diﬀ erent age groups in the eﬀ ect 
of screening on any outcome, in intention-to-treat or per-
protocol analyses (ﬁ gure 4; data shown for incidence of 
colorectal cancer at all sites).
Discussion
Findings from this large randomised trial have shown 
that both incidence of and mortality from colorectal 
cancer are signiﬁ cantly reduced in people undergoing a 
single ﬂ exible sigmoidoscopy examination between 
55 and 64 years of age. 
After 11 years of follow-up, colorectal cancer incidence 
was reduced by a third and colorectal cancer mortality by 
more than 40% in those who underwent screening. 
Conﬁ ning results to the rectum and sigmoid colon, 
incidence was reduced by half in those who were 
screened. Of the 215 distal cancers diagnosed in this 
group during 11 years of follow-up, 126 (59%) were 
detected at screening.7 Incidence of distal cancers in the 
postscreening period was very low, and so far there seems 
to be little attenuation of the protective eﬀ ect of the 
screening test (ﬁ gure 2D, ﬁ gure 3). 
Two other trials of ﬂ exible sigmoidoscopy screening 
will be reported soon. The Italian trial, SCORE,22 is based 
on the UK trial protocol and is examining the eﬀ ect of 
one screen undertaken between 55 and 64 years of age, 
with polypectomy of small lesions (<10 mm) done at 
screening. The US trial, PLCO,23 is examining the eﬀ ect 
of screening every 3–5 years during 55–74 years of age. In 
this trial, people with abnormalities detected at screening 
are referred to their personal physician for diagnostic 
work-up. The Norwegian trial, NORCCAP,24 which is also 
examining the eﬀ ect of once-only sigmoidoscopy at ages 
55–64 years, reported results after 7 years of follow-up, at 
which time no reduction in colorectal cancer incidence 
was detected.
All colorectal cancer diagnoses received from cancer 
registries were veriﬁ ed with clinical and pathology 
records from the hospitals. Colorectal cancer deaths were 
deﬁ ned by the ONS, but additionally, underlying causes 
of death in people with a previous diagnosis of colorectal 
cancer were reclassiﬁ ed according to rules described in 
the webappendix. An independent expert coder, who was 
masked to the trial allocation, recoded the underlying 
cause of death, relying on information provided on the 
death certiﬁ cate supplemented with clinical information 
when available. Full access to medical records, as in 
previous studies,25,26 was not possible. This approach, we 
believe, is justiﬁ able because Ederer and colleagues25 
showed that diﬀ erent death veriﬁ cation methods yielded 
largely similar numbers of endpoints in the Minnesota 
faecal occult blood screening trial. In our study we 
recorded 727 deaths attributed to colorectal cancer 
according to the ONS. The independent reviewer 
identiﬁ ed a further 131 that could probably be attributed 
to colorectal cancer, suggesting an underestimation of 
colorectal cancer deaths of 15·3% in this series. However, 
use of the reviewer’s classiﬁ cation of deaths did not 
change signiﬁ cantly the eﬀ ect of the intervention on 
colorectal cancer mortality.
The relative eﬀ ects of screening on colorectal cancer 
incidence and mortality were estimated with standard 
intention-to-treat analyses, which compare outcomes in 
the control group with the entire group invited for 
screening irrespective of attendance. Non-attendance, 
which was 29% in this trial, dilutes the observed eﬀ ect of 
screening. Cuzick and colleagues’20 method can be used 
to estimate relative risk in attenders compared with the 
control group, adjusted for the rate of disease in non-
attenders. Unusually, colorectal cancer incidence and 
mortality rates in this trial were very similar in non-
attenders and controls (table 2), suggesting that the 
underlying rates in attenders were also very similar. 
Nevertheless, we adjusted for non-compliance since the 
method generates more realistic CIs.
A national bowel cancer screening programme 
(NBCSP) based on faecal occult blood testing was 
introduced in a staged manner across England from 
July, 2006, and some of the participants in our trial took 
part in this national programme. We matched our 
dataset with the NBCSP database and noted that 59 of 
the colorectal cancers had been diagnosed within the 
screening programme (45 control group and 
14 intervention group). We did a sensitivity analysis 
excluding these cancers on the assumption that they 
might not have been diagnosed in the absence of 
screening. The results were almost unchanged (data 
not shown).
Results of previous case-control studies suggested that 
ﬂ exible sigmoidoscopy could reduce distal colon cancer 
incidence and mortality by around 70%.12–14 So far the 
cumulative reduction in people attending screening in 
our study is 50%. This lower value is most likely 
attributable to dominance of screen-detected prevalent 
cancers in the ﬁ rst 4 years of follow-up (ﬁ gure 2D), and 
only after this point did a beneﬁ t in terms of incidence 
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reduction become apparent. If incidence in the screened 
participants remains low during further follow-up, the 
magnitude of reduction in cumulative incidence will 
continue to increase. The cohort will need to be followed 
up to examine the important issue of the long-term 
eﬀ ects of one screening examination.
We recorded no eﬀ ect of screening on the incidence of 
cancers in the proximal colon. This result might be 
expected since ﬂ exible sigmoidoscopy does not examine 
the proximal colon. Several studies11,27,28 have shown that 
the risk of cancer beyond the reach of the sigmoidoscope 
can be predicted from the characteristics of adenomas 
detected in the rectum and sigmoid colon, and this ﬁ nding 
was the basis for selection for baseline colonoscopy and 
entry into a colonoscopic surveillance programme in this 
trial. Screened participants who had high-risk polyps were 
referred for colonoscopy, whereas participants who had no 
polyps or only low-risk polyps were discharged and their 
proximal colon was never examined. As a result, 
colonoscopy was undertaken in 5% of individuals attending 
screening. In the PLCO and NORCCAP trials,23,24 criteria 
for colonoscopy after ﬂ exible sigmoidoscopy screening 
were based on detection of any adenoma or any abnormality, 
respectively, and consequently colonoscopy rates were 
three to four times higher than in our study. Whether a 
signiﬁ cant reduction in incidence of proximal colon cancer 
is recorded with these protocols will be of interest.
Rates of all-cause mortality excluding colorectal cancer 
were slightly, although not signiﬁ cantly, reduced in the 
intervention group compared with the control group. 
This reassuring ﬁ nding suggests that the screening did 
not have unexpected harms.
Economic analyses29,30 suggest that, with pre-existing 
assumptions, a once-only ﬂ exible sigmoidoscopy screen 
at age 55 or 60 years would be cost saving, largely 
because of the avoided costs of treatment resulting from 
the reduction in incidence. These economic analyses 
now need to be repeated with the inclusion of our trial 
data. Factors that will aﬀ ect the estimated costs of 
ﬂ exible sigmoidoscopy screening are the present and 
projected costs of treating colorectal cancer31 and the 
method of delivery of the screening procedure. 
Adequately trained nurse practitioners can undertake 
ﬂ exible sigmoidoscopy as competently as can 
gastroenterologists,32,33 and public acceptance of nurse-
led ﬂ exible sigmoidoscopy screening is high.34,35 If 
ﬂ exible sigmoidoscopy screening were introduced into a 
national cancer screening programme, both medical 
and non-medical endoscopy practitioners participating 
in the programme should meet quality standards and 
undertake a minimum number of procedures to allow 
precise measurement of key parameters in a quality 
assurance programme, as is required for the English 
NBCSP based on FOBT.36,37
A limitation of the trial is that rather than inviting the 
whole population aged 55–64 years for screening, the 
trial used a two-stage recruitment procedure whereby 
eligible individuals were randomly assigned only if they 
responded to a questionnaire and indicated that they 
would be likely to attend screening. This procedure 
increased the power of the study to examine the eﬃ  cacy 
of ﬂ exible sigmoidoscopy. However, it meant that the 
compliance rate in the trial was higher than would be 
expected in a population-based programme, at least in 
its early years. We are not able to establish whether the 
observed eﬀ ect of screening is generalisable to non-
participants (those who did not indicate interest on the 
initial questionnaire). Had we invited the whole 
population directly, these individuals would probably 
not have taken up the oﬀ er of screening and we would 
have gained no more information about eﬃ  cacy in this 
group. Colorectal cancer incidence in our control group 
was 149 per 1000 person-years, which is almost exactly 
as expected from the general population incidence38 
in a group aged 55–64 years followed up for just over 
10 years (data not shown). Thus our study population is 
representative in terms of risk of colorectal cancer, and 
there is no reason to believe that the potential 
beneﬁ ts of screening would diﬀ er in people who chose 
not to participate.
The results from our trial show that ﬂ exible sigmoidoscopy 
is a safe and practical test and, when oﬀ ered only once to 
people between ages 55 and 64 years, confers a substantial 
and long lasting protection from colorectal cancer.
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